4.7 Review

Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases

期刊

JOURNAL OF PERSONALIZED MEDICINE
卷 12, 期 7, 页码 -

出版社

MDPI
DOI: 10.3390/jpm12071021

关键词

relaxin-2; relaxin; biomarker; cardiovascular disease; cardiac; heart

资金

  1. National Institute of Health Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III Madrid, Spain [PI21/01145, RD16/0012/0014]
  2. European Regional Development Fund (FEDER) [734899]
  3. European Union [734899]
  4. Axencia Galega de Innovacion (GAIN): Axudas do programa de consolidacion e estruturacion de unidades de investigacion competitivas [GPC IN607B 2021 108]
  5. Xunta de Galicia
  6. PFIS Program of the Spanish Ministry of Science (Spain)
  7. Instituto de Salud Carlos III (Spain)

向作者/读者索取更多资源

Relaxin-2 plays a crucial role in regulating various physiological and pathological processes in the cardiovascular system, including cardiac metabolism, vasodilation, reversal of fibrosis and hypertrophy, reduction of inflammation and oxidative stress, stimulation of angiogenesis, and inotropic and chronotropic effects. It has potential therapeutic applications in cardiac injury and different cardiovascular disorders, and is also proposed as a promising biomarker for cardiovascular health and disease.
The pleiotropic hormone relaxin-2 plays a pivotal role in the physiology and pathology of the cardiovascular system. Relaxin-2 exerts relevant regulatory functions in cardiovascular tissues through the specific receptor relaxin family peptide receptor 1 (RXFP1) in the regulation of cardiac metabolism; the induction of vasodilatation; the reversion of fibrosis and hypertrophy; the reduction of inflammation, oxidative stress, and apoptosis; and the stimulation of angiogenesis, with inotropic and chronotropic effects as well. Recent preclinical and clinical outcomes have encouraged the potential use of relaxin-2 (or its recombinant form, known as serelaxin) as a therapeutic strategy during cardiac injury and/or in patients suffering from different cardiovascular disarrangements, especially heart failure. Furthermore, relaxin-2 has been proposed as a promising biomarker of cardiovascular health and disease. In this review, we emphasize the relevance of the endogenous hormone relaxin-2 as a useful diagnostic biomarker in different backgrounds of cardiovascular pathology, such as heart failure, atrial fibrillation, myocardial infarction, ischemic heart disease, aortic valve disease, hypertension, and atherosclerosis, which could be relevant in daily clinical practice and could contribute to comprehending the specific role of relaxin-2 in cardiovascular diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据